Merz Aesthetics®Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only Ultrasound Solution With Integrated Real-Time Visualization
Latest Intention for USE Expands to Improve the Appearance of Skin Laxity on the Posterior and Anterior Armsand Abdomen, to launch in the United States before worldwide expansion.
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the upcoming availability of UltherapyPRIMEto improve the appearance of skin laxity on the anterior arms and posterior arms, and abdomen.
Ultherapy PRIME is the only solution with integrated real-time visualization to treat the upper face, lower face, neck, décolleté, and now the body*.1 The new indications will launch in the United States before expanding to markets worldwide, with commercial rollout in EMEA planned for early 2026.** We are excited to share updates with our customers soon and look forward to supporting practices and patients with these innovative solutions.
“This indication expansion is proof of our incredible momentum, following last year’s successful Ultherapy PRIME launch,” said Bob Rhatigan, CEO, Merz Aesthetics. “By extending our reach from face*** to body*, we’re unlocking new treatment possibilities, meeting rising patient demand, and reinforcing our leadership in non-invasive skin lifting and tightening.”
Ultherapy PRIME builds on the legacy of Ultherapy®, which was recognized by a panel of experts as the Gold Standard in non-invasive skin lifting and tightening with over 3.5 million treatments performed§ globally and a 95% patient satisfaction rate.1-3 The skin lifting market is expanding rapidly and is expected to grow approximately 9% by 2030, driven largely by life stage (post-partum, menopause), and weight loss related skin laxity patient demographics.4
Ultherapy PRIME stimulates the body’s natural collagen and elastin production precisely where it’s needed. In just one session, Ultherapy PRIME lifts and tightens the upper face, lower face, neck, and décolleté. Now, Ultherapy PRIME also firms and tones the skin on the arms and abdomen - with no downtime and suitable for all skin tones1,5. It offers personalized, visible natural-looking results, along with younger looking skin, that can last up to a year or more on the face*** and 6 months or more on the arms and abdomen.4-7
“The Ultherapy PRIME platform offers all the signature benefits of Ultherapy for non-invasive skin lifting and tightening, plus the ability to improve skin laxity on the abdomen and arms in a single session,” said Dr. Sabrina Fabi, world-renowned Double Board-Certified Dermatologist and Dermatological Cosmetic Surgeon from San Diego, California. “This is of great value for my patients who want to keep the skin on their body looking as youthful as the skin on their face.”4,6,7
“These new indications for arms and abdomen* strengthen Ultherapy PRIME’s position as a multi-purpose skin lifting, tightening, and firming treatment solution,” said Alexis Stern, Chief Marketing Officer, Merz Aesthetics. “This exciting journey started a year ago when we launched Ultherapy PRIME as a platform to lift the face*** and with this next phase of growth for the platform we are now able to firm and tone the body.”*,1,6
To highlight the latest body* indications, Merz Aesthetics is also launching a new global campaign for Ultherapy PRIME. To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables and devices designed to meet each patient’s needs. Being family owned for more than 115 years; Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
About Ultherapy:
The Ulthera System is intended to lift and sculpt the upper face, lower face, neck and décolleté, and to improve the appearance of skin laxity on the abdomen, anterior arms, and posterior arms. Reported adverse events from post marketing surveillance are available in the Instructions for Use (IFU). Please reference the IFU for additional information, including specific indications in your country, full product and safety information, and possible side effects.
The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Talk to your practitioner for additional safety information and possible side effects.
*Indicated to improve the appearance of skin laxity on the abdomen, anterior arms and posterior arms.
**Timelines may vary by market based on regulatory approvals and will begin as soon as all required registrations are received.
***Face refers to the cleared indications for Ultherapy PRIME.
§Treatments performed with Ultherapy and Ultherapy PRIME.
References:
- Ulthera® Instructions for Use.
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Ultherapy PRIME Letter of Treatments Sold. Merz Aesthetics®, Herring L, Sr Director, Regulatory Affairs, Advertising and Promotion. July 16, 2025. Data on File.
- Data on File. Merz Custom Market Forecasting 2025.
- Marquardt K, Hartmann C, Wegener F, et al. Microfocused ultrasound with visualization induces remodeling of collagen and elastin within the skin. J Cosmet Dermatol. 2025;24(1):e16638. doi:10.1111/jocd.16638.
- Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
- Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
- Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
- Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
© 2025 Ulthera, Inc. All Rights Reserved. MERZ AESTHETICS is a trademark and/or registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera, Inc. in the U.S. and/or certain other countries.
Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and international patents to which Ulthera, Inc. has rights are issued, published, or pending.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251105361450/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Unveils New Smart Single Board Computers (SBC) to Help Accelerate Intelligent Device Development, Rapid Prototyping and Cutting Development Costs5.11.2025 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, has launched three new smart single board computers (SBC). The QSM368Z, QSM560DR, and QSM668SR are designed to give developers more choice and speed up product development of intelligent solutions and digital transformation. Each board is cost-effective, fully certified, and offers a wide range of options for connectivity, operating system and memory options to suit different application needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105179097/en/ Quectel unveils new smart single board computers (SBC) to help accelerate intelligent device development, rapid prototyping and cutting development costs “These boards are fully finished hardware that can be easily integrated inside customers’ larger systems across a wide range of IoT use cases,” commented Raymond Wang, Head of Smart SoC, Quectel Wireless Solutions. “Provided in a ready-to-use, singl
First in Human Ischemic VT Ablation Successfully Performed in iCMR5.11.2025 16:55:00 CET | Press release
Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105120761/en/ Imricor’s NorthStar® Mapping System The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation procedures guided by real-time MRI and Imricor’s NorthStar® Mapping System. Regarding the VT procedure, Dr. Kemme, stated: “This procedure is part of an international research programme. The MRI imaging shows us precisely where the myocardial infarction took place; therefore, we can send the catheter to the exact spot. This information can make ablation possi
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions5.11.2025 16:12:00 CET | Press release
SIS Medical AG, a Swiss manufacturer of the Super-High-Pressure PTCA balloon catheter (OPN NC), is pleased to announce that the results of the investigator-initiated VICTORY trial were presented during the late-breaking clinical session at TCT 2025 by the Cardiovascular Research Foundation (CRF). The randomized, multi-center clinical study was designed to compare the safety and efficacy between the OPN and IVL devices for lesion preparation and optimized stent expansion in highly complex calcified coronary lesions, deploying a drug-eluting stent (DES). Coronary artery calcium affects approximately one-third of patients undergoing PCI and is a key contributor to procedural and stent failure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105812157/en/ "With a similar safety profile, OPN can be a feasible and faster alternative to IVL." Dr. M. Bossard, Senior Physician at Luzerner Kantonsspital, Switzerland A total of 282 p
Doha Debates Explores the Role of Ancient Wisdom in Today’s World5.11.2025 16:06:00 CET | Press release
Experts and students debate whether ancient wisdom holds answers for modern societies As the world grapples with questions of meaning and moral direction, Doha Debates takes on a fundamental question: Should ancient wisdom guide today’s societies? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105183709/en/ Guest speakers and participating students gather on the Doha Debates stage to discuss a fundamental question “Should ancient wisdom guide today’s societies?” — part of the show’s exploration of timeless questions shaping our world today. (Photo: AETOSWire) In this episode of the new flagship season, moderated by Dareen Abughaida, students from across Qatar join three global thinkers to wrestle with a timeless dilemma: whether the answers to our most pressing problems lie in tradition or in bold new ideas. Wael Hallaq, Avalon Foundation Professor in the Humanities at Columbia University, critiques what he calls the “mor
Versa Delivers Proven Firewall Performance and Security Effectiveness Validated by Independent Testing5.11.2025 15:30:00 CET | Press release
Versa One of Only Three Recommended Products, Maintaining Position as Performance Leader by Delivering Fastest Throughput While Achieving a 99.43% Security Effectiveness Score Versa, the global leader in unified networking and security, today announced that its Next-Generation Firewall received CyberRatings.org’s highest “Recommended” rating for the ninth consecutive year. In the newly published Q3 2025 Enterprise Firewall report, based on independent testing by NSS Labs, Versa delivered 100% scores in critical categories like malware and exploit evasion resistance, and achieved a leading 7,626 Mbps rated throughput, over twice as fast as competing solutions. Selecting cybersecurity solutions requires unbiased, real-world performance testing and evaluation. CyberRatings.org provides IT and security leaders with data-driven results to guide investment decisions. In this latest assessment, Versa ranked among the top three vendors for Security Effectiveness and delivered more than twice t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom